Pulse Biosciences, Inc. (PLSE) shareholders
Close on Nov 17, 2026Market cap $3.20BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Robert W. Duggan | 49,706,423 | 71.90% | 13D (active) amendment | May 11, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PLSE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,466,702 | 2.06% | $40.67M | +126,924 | 0.00% |
| Bank Of America Corp /De/ | 1,446,611 | 2.03% | $40.11M | +580,550 | 0.00% |
| Vanguard Capital Management LLC | 788,640 | 1.11% | $21.87M | −27,212 | 0.00% |
| Portolan Capital Management, LLC | 753,333 | 1.06% | $20.89M | +19,961 | 0.78% |
| Price T Rowe Associates Inc /Md/ | 748,638 | 1.05% | $20.76M | +733,779 | 0.00% |
| Balyasny Asset Management L.P. | 718,103 | 1.01% | $19.91M | +452,939 | 0.02% |
| Citadel Advisors LLC | 626,514 | 0.88% | $17.37M | +484,364 | 0.00% |
| Geode Capital Management, LLC | 536,276 | 0.75% | $14.87M | +44,330 | 0.00% |
| State Street Corp | 529,624 | 0.74% | $14.69M | +72,697 | 0.00% |
| Massachusetts Financial Services Co /Ma/ | 462,734 | 0.65% | $12.83M | −165 | 0.00% |
| UBS Group AG | 275,669 | 0.39% | $7.64M | +241,715 | 0.00% |
| Griffin Asset Management, Inc. | 227,285 | 0.32% | $6.30M | +2,108 | 0.66% |
| Vanguard Portfolio Management LLC | 179,497 | 0.25% | $4.98M | +14,296 | 0.00% |
| Northern Trust Corp | 173,590 | 0.24% | $4.81M | −13,682 | 0.00% |
| Charles Schwab Investment Management Inc | 151,991 | 0.21% | $4.21M | +4,223 | 0.00% |
| Vanguard Fiduciary Trust Co | 131,253 | 0.18% | $3.64M | +647 | 0.00% |
| Point72 Asset Management, L.P. | 106,457 | 0.15% | $2.95M | New | 0.00% |
| Norges Bank | 105,647 | 0.15% | $2.93M | New | 0.00% |
| Nuveen, LLC | 101,683 | 0.14% | $2.82M | +56,248 | 0.00% |
| Panoramic Capital, LLC | 98,054 | 0.14% | $2.72M | +40,000 | 1.17% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 106 | 11M | 15.0% | 22 / 43 | 23 / 10 | 3M | 0M |
| Q1 2026 | 96 | 8M | 10.9% | 33 / 27 | 23 / 15 | 3M | 0M |
| Q4 2025 | 82 | 6M | 8.9% | 11 / 24 | 27 / 13 | 1M | 0M |
| Q3 2025 | 84 | 6M | 8.2% | 10 / 26 | 27 / 12 | 0M | 0M |
| Q2 2025 | 86 | 6M | 8.4% | 11 / 30 | 28 / 9 | 1M | 0M |
| Q1 2025 | 84 | 6M | 8.0% | 18 / 23 | 29 / 6 | 1M | 1M |
| Q4 2024 | 73 | 6M | 8.4% | 13 / 31 | 17 / 12 | 1M | 0M |
| Q3 2024 | 72 | 6M | 7.9% | 20 / 23 | 17 / 3 | 2M | 0M |
| Q2 2024 | 57 | 5M | 6.8% | 8 / 24 | 17 / 12 | 0M | 0M |
| Q1 2024 | 61 | 5M | 6.8% | 14 / 11 | 23 / 3 | 1M | 0M |
| Q4 2023 | 50 | 4M | 6.3% | 11 / 17 | 12 / 4 | 1M | 0M |
| Q3 2023 | 43 | 4M | 5.4% | 4 / 17 | 12 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
110 funds held PLSE in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PLSE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 554,612 | 0.78% | $15.38M | 0.00% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 513,041 | 0.72% | $12.83M | 0.01% | May 31, 2026 |
| iShares Russell 2000 ETF | 487,179 | 0.68% | $13.51M | 0.02% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 485,300 | 0.68% | $13.46M | 0.09% | Jun 30, 2026 |
| MFS New Discovery Fund | 339,453 | 0.48% | $8.49M | 0.40% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 215,880 | 0.30% | $5.99M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 210,120 | 0.29% | $7.38M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 174,265 | 0.24% | $4.83M | 0.03% | Jun 30, 2026 |
| MFS New Discovery Series | 122,295 | 0.17% | $3.39M | 0.41% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 94,628 | 0.13% | $2.37M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 91,223 | 0.13% | $2.28M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 86,743 | 0.12% | $2.17M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 61,907 | 0.09% | $1.72M | 0.11% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 60,556 | 0.08% | $1.51M | 0.01% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF | 53,019 | 0.07% | $1.47M | 0.97% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul A. Laviolette | Chief Executive Officer, Director | 15,000 | 0.02% | May 11, 2026 |
| Darrin Uecker | Chief Technology Officer, Director | 142,872 | 0.20% | Apr 3, 2026 |
| Liane Rae Teplitsky | Chief Operating Officer | 4,095 | 0.01% | Sep 2, 2026 |
| Jon Skinner | Chief Financial Officer | – | – | Aug 28, 2026 |
| Kevin Patrick Danahy | Chief Commercial Officer | 43,298 | 0.06% | Feb 23, 2026 |
| Steven Weber | Principal Accounting Officer | – | – | Jul 16, 2025 |
| Mahkam Zanganeh | Director | 873,469 | 1.22% | Jun 15, 2026 |
| Manmeet Singh Soni | Director | – | – | Jun 15, 2026 |
| Robert W. Duggan | Director, 10% owner | 49,450,345 | 69.33% | Jun 15, 2026 |
| Maria Sainz | Director | – | – | Jun 15, 2026 |
| den Broek Richard van | Director | – | – | Jun 15, 2026 |
| Burke Thomas Barrett | – | 63,172 | 0.09% | Dec 20, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Liane Rae Teplitsky Chief Operating Officer | Sep 1, 2026 | Buy | +1,001 | $49.95 | $50.00K | 4,095 |
| Liane Rae Teplitsky Chief Operating Officer | Aug 31, 2026 | Buy | +1,024 | $48.80 | $49.97K | 3,094 |
| Liane Rae Teplitsky Chief Operating Officer | Aug 28, 2026 | Buy | +1,034 | $48.35 | $49.99K | 2,070 |
| Liane Rae Teplitsky Chief Operating Officer | Aug 26, 2026 | Buy | +1,036 | $48.24 | $49.98K | 1,036 |
| Robert W. Duggan Director, 10% owner | May 11, 2026 | Buy | +660,233 | $19.69 | $13.00M | 48,370,047 |
| Paul A. Laviolette Chief Executive Officer, Director | May 11, 2026 | Buy | +15,000 | $19.69 | $295.35K | 15,000 |
| Robert W. Duggan Director, 10% owner | May 11, 2026 | Buy | +660,233 | $19.69 | $13.00M | 48,211,433 |
| Paul A. Laviolette Chief Executive Officer, Director | May 11, 2026 | Buy | +15,000 | $19.69 | $295.35K | 15,846 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −5,000 | $23.64 | $118.20K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 18, 2026 | Option exercise | +5,000 | $1.53 | $7.65K | 48,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −20,000 | $23.63 | $472.60K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 17, 2026 | Option exercise | +20,000 | $1.53 | $30.60K | 63,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 13, 2026 | Sale(10b5-1 plan) | −20,000 | $23.53 | $470.60K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 13, 2026 | Option exercise | +20,000 | $1.53 | $30.60K | 63,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 12, 2026 | Option exercise | +20,000 | $1.53 | $30.60K | 63,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −20,000 | $23.37 | $467.40K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 11, 2026 | Option exercise | +20,000 | $1.53 | $30.60K | 63,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 11, 2026 | Sale(10b5-1 plan) | −20,000 | $25.20 | $504.00K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 10, 2026 | Sale(10b5-1 plan) | −20,000 | $23.52 | $470.40K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 10, 2026 | Option exercise | +20,000 | $1.53 | $30.60K | 63,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 9, 2026 | Sale(10b5-1 plan) | −20,000 | $21.45 | $429.00K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Feb 9, 2026 | Option exercise | +20,000 | $1.53 | $30.60K | 63,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Oct 2, 2025 | Option exercise | +4,600 | $1.53 | $7.04K | 47,898 |
| Kevin Patrick Danahy Chief Commercial Officer | Oct 2, 2025 | Sale(10b5-1 plan) | −4,600 | $18.53 | $85.24K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Sep 19, 2025 | Option exercise | +400 | $1.53 | $612 | 43,698 |
| Kevin Patrick Danahy Chief Commercial Officer | Sep 19, 2025 | Sale(10b5-1 plan) | −400 | $18.48 | $7.39K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Sep 18, 2025 | Sale(10b5-1 plan) | −20,000 | $18.49 | $369.80K | 43,298 |
| Kevin Patrick Danahy Chief Commercial Officer | Sep 18, 2025 | Option exercise | +20,000 | $1.53 | $30.60K | 63,298 |
| Darrin Uecker Chief Technology Officer, Director | Sep 17, 2025 | Option exercise | +20,000 | $4.00 | $80.00K | 142,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 17, 2025 | Option exercise | +61,534 | $4.00 | $246.14K | 184,406 |
| Darrin Uecker Chief Technology Officer, Director | Sep 17, 2025 | Sale(10b5-1 plan) | −20,000 | $16.21 | $324.20K | 122,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 17, 2025 | Option exercise | +100,000 | $4.00 | $400.00K | 284,406 |
| Darrin Uecker Chief Technology Officer, Director | Sep 16, 2025 | Sale(10b5-1 plan) | −25,000 | $16.28 | $407.00K | 122,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 16, 2025 | Option exercise | +25,000 | $4.00 | $100.00K | 147,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 15, 2025 | Option exercise | +25,000 | $4.00 | $100.00K | 147,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 15, 2025 | Sale(10b5-1 plan) | −25,000 | $15.77 | $394.25K | 122,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 12, 2025 | Option exercise | +25,000 | $4.00 | $100.00K | 147,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 12, 2025 | Sale(10b5-1 plan) | −25,000 | $14.32 | $358.00K | 122,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 11, 2025 | Sale(10b5-1 plan) | −25,000 | $14.78 | $369.50K | 122,872 |
| Darrin Uecker Chief Technology Officer, Director | Sep 11, 2025 | Option exercise | +25,000 | $4.00 | $100.00K | 147,872 |
| Robert W. Duggan Director, 10% owner | Sep 10, 2025 | Buy | +34,659 | $14.66 | $508.10K | 47,551,200 |
| Darrin Uecker Chief Technology Officer, Director | Jun 13, 2025 | Sale | −15,000 | $15.98 | $239.70K | 122,872 |
| Darrin Uecker Chief Technology Officer, Director | Jun 12, 2025 | Sale | −15,000 | $16.40 | $246.00K | 137,872 |
| Mahkam Zanganeh Director | Feb 3, 2025 | Option exercise | +30,121 | $11.00 | $331.33K | 725,395 |
| Mahkam Zanganeh Director | Jan 24, 2025 | Option exercise | +30,121 | $11.00 | $331.33K | 695,274 |
| Robert W. Duggan Director, 10% owner | Dec 18, 2024 | Option exercise | +49,312 | $11.00 | $542.43K | 450,189 |
| Robert W. Duggan Director, 10% owner | Dec 18, 2024 | Option exercise | +69,020 | $11.00 | $759.22K | 630,109 |
| Robert W. Duggan Director, 10% owner | Dec 18, 2024 | Option exercise | +5,187,824 | $11.00 | $57.07M | 47,516,541 |
| Robert W. Duggan Director, 10% owner | Dec 13, 2024 | Buy | +55,256 | $17.18 | $949.30K | 42,328,717 |
| Robert W. Duggan Director, 10% owner | Dec 12, 2024 | Buy | +45,404 | $17.13 | $777.77K | 42,273,461 |
| Burke Thomas Barrett – | Dec 11, 2024 | Sale | −50,000 | $17.42 | $871.00K | 63,172 |
| Robert W. Duggan Director, 10% owner | Dec 11, 2024 | Buy | +50,000 | $17.42 | $871.00K | 42,228,057 |
| Robert W. Duggan Director, 10% owner | Dec 11, 2024 | Buy | +6,054 | $16.74 | $101.34K | 42,178,057 |
| Mitchell E. Levinson Chief Strategy Officer | Sep 24, 2024 | Option exercise | +3,000 | $11.00 | $33.00K | 93,880 |
| Mitchell E. Levinson Chief Strategy Officer | Sep 24, 2024 | Option exercise | +1,240 | $11.00 | $13.64K | 21,240 |
| Mitchell E. Levinson Chief Strategy Officer | Sep 24, 2024 | Option exercise | +322 | $11.00 | $3.54K | 8,321 |
| Mitchell E. Levinson Chief Strategy Officer | Sep 24, 2024 | Option exercise | +322 | $11.00 | $3.54K | 8,421 |
| Mitchell E. Levinson Chief Strategy Officer | Sep 24, 2024 | Option exercise | +322 | $11.00 | $3.54K | 8,521 |
| Robert W. Duggan Director, 10% owner | Sep 12, 2024 | Buy | +145,140 | $14.41 | $2.09M | 47,709,140 |
| Robert W. Duggan Director, 10% owner | Sep 11, 2024 | Buy | +12,800 | $14.77 | $189.06K | 47,564,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pulse Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 127,247 shares on Sep 4, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kevin Patrick Danahy Officer | Feb 12, 2026 | 50,000 | $1.26M | Feb 12, 2026 | Exercise of Stock Options |
| Kevin Patrick Danahy Officer | Feb 9, 2026 | 75,000 | $1.56M | Feb 9, 2026 | Exercise of Stock Options |
| Kevin Patrick Danahy Officer | Sep 18, 2025 | 25,000 | $406.75K | Sep 18, 2025 | Exercise of Stock Options |
| Darrin Uecker Director, Officer | Sep 11, 2025 | 120,000 | $1.77M | Sep 11, 2025 | Exercise of Stock Options |
| Darrin Uecker Officer, Director | Jun 13, 2025 | 15,000 | $239.74K | Jun 13, 2025 | Restricted stock vesting under a registered plan |
| Darrin Uecker Officer, Director | Jun 12, 2025 | 15,000 | $246.05K | Jun 12, 2025 | Restricted stock vesting under a registered plan |
See a number that looks wrong?